Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.814 USD | +1.75% | -10.88% | +0.99% |
04-25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
04-25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.99% | 79.16M | |
+33.15% | 698B | |
+26.51% | 568B | |
-4.34% | 358B | |
+19.26% | 328B | |
+3.95% | 283B | |
+16.45% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.66% | 165B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating